Monitoring low-dose Warfarin therapy by a central laboratory and implications for clinical trials and patient care

American Journal of Cardiology

Volumn 78, Issue 9, 1996, Pages 1074-1076

  Raskob, Gary E ^a   Durica, Sherri S ^a   Owen, Willis L ^a   Comp, Philip C ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

AGED; ARTICLE; BLOOD; CLINICAL TRIAL; FEMALE; HUMAN; LABORATORY; LABORATORY DIAGNOSIS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PATIENT CARE PLANNING; PROSPECTIVE STUDY;

AGED; ANTICOAGULANTS; CLINICAL TRIALS; FEMALE; HUMANS; LABORATORIES; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PATIENT CARE PLANNING; PROSPECTIVE STUDIES; SPECIMEN HANDLING; WARFARIN;

EID: 0030294223     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00543-7     Document Type: Article

References (13)

1. Bern MM, Lokich JJ, Wallach SR, Both A, Benotti P, Arkin C, Greco F, Huberman M, Moore C. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990;112:423-428.
2. Poller L, McKernan A, Thomson JM, Elstein M, Hirsch PJ, Jones JB. Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. Br Med J 1987;295:1309-1312.
3. Meade TW, Wilkes HC, Stirling Y, Brennan PJ, Kelleher C, Browne W. Randomized controlled trial of low dose warfarin in the primary prevention of ischaemic heart disease in men at high risk: design and pilot study. Eur Heart J 1988;9:836-843.
4. Goodman SG, Langer A, Durica S, Raskob G, Comp P, Gray R, Hall J, Kelley RP, Hua TA, Lee RJ, Fuster V. Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Am J Cardiol 1994;74:657-661.
5. Hirsh J, Poller L. The International Normalized Ratio. A guide to understanding and correcting its problems. Arch Intern Med 1994;154:282-288.
6. Raskob GE, Durica SS, Morrissey JH, Owen WL, Comp PC. Effect of treatment with low-dose warfarin-aspirin on activated factor VII. Blood 1995;85:3034-3039.
7. Kaatz SS, White RH, Hill J, Mascha E, Humphries JE, Becker DM. Accuracy of laboratory and portable monitor International Normalized Ratio determinations. Comparison with a criterion standard. Arch Intern Med 1995;155:1861-1867.
8. Le DT, Weibert RT, Sevilla BK, Donnelly KJ, Rapaport SI. The International Normalized Ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. Ann Intern Med 1994;120:552-558.
9. Anderson DR, Harrison L, Hirsh J. Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy. Arch Intern Med 1993;153:1441-1447.
10. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrhematic atrial fibrillation. N Engl J Med 1990;323:1505-1511.
11. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling C, Garnick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, et al, for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-1412.
12. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest 1995;108(suppl):352s-359s.
13. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey HI. Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 1995;108(suppl):231s-246s.